Literature DB >> 27709552

A new ten-gene risk fraction model serving as prognostic indicator for clinical outcome of multiple myeloma.

Ai-Xin Hu1, Zhi-Yong Huang2, Ping Liu3, Tian Xiang4, Shi Yan5, Li Zhang6.   

Abstract

Multiple myeloma (MM) is a kind of aggressive tumor prevalent with high heterogeneity. Abnormal expression of certain genes may lead to the occurrence and development of MM. Nowadays, it is not commonly seen in clinical research to predict the prognostic circumstances of patients with MM by multiple gene expression profiling method. Identification of potential genes in prognostic process could be beneficial for clinical management of MM. Therefore, we aimed to build a risk fraction model to screen out the prognostic indicator for clinical outcome of MM. Microarray data were downloaded from the Genome Expression Omnibus (GEO) datasets with accession numbers GSE24080 and GSE57317. A total of 279 samples were selected out randomly. Besides, a risk formula was constructed and verified in the dataset. Time-dependent receiver operating characteristic (ROC) curve was applied in evaluating the accurate prognostic conditions of patients. Finally, a ten genes model in the training dataset was found to be closely related to the survival condition of MM patients. Patients with MM were divided into two groups, high-risk and low-risk, by the expression of these ten genes, and significant statistical difference was found between the two groups. Furthermore, the result of multivariate cox regression and stratified analysis indicated that this model was independent of other clinical phenotypes. ROC curves also showed its feasibility to predict the survival status of MM patients. Our results demonstrated that the fraction risk model constructed by the selected ten genes could be used to predict survival status of multiple myeloma patients, which could also help in improvement of prognostic and therapeutic tool of MM.

Entities:  

Keywords:  Genes; Microarray expression profiling; Multiple myeloma; Prognostic indicator; Survival rates

Year:  2016        PMID: 27709552     DOI: 10.1007/s13277-016-5449-4

Source DB:  PubMed          Journal:  Tumour Biol        ISSN: 1010-4283


  20 in total

1.  Validation study of a quantitative multigene reverse transcriptase-polymerase chain reaction assay for assessment of recurrence risk in patients with stage II colon cancer.

Authors:  Richard G Gray; Philip Quirke; Kelly Handley; Margarita Lopatin; Laura Magill; Frederick L Baehner; Claire Beaumont; Kim M Clark-Langone; Carl N Yoshizawa; Mark Lee; Drew Watson; Steven Shak; David J Kerr
Journal:  J Clin Oncol       Date:  2011-11-07       Impact factor: 44.544

2.  RefPlus: an R package extending the RMA Algorithm.

Authors:  Chris Harbron; Kai-Ming Chang; Marie C South
Journal:  Bioinformatics       Date:  2007-07-10       Impact factor: 6.937

3.  The MicroArray Quality Control (MAQC)-II study of common practices for the development and validation of microarray-based predictive models.

Authors:  Leming Shi; Gregory Campbell; Wendell D Jones; Fabien Campagne; Zhining Wen; Stephen J Walker; Zhenqiang Su; Tzu-Ming Chu; Federico M Goodsaid; Lajos Pusztai; John D Shaughnessy; André Oberthuer; Russell S Thomas; Richard S Paules; Mark Fielden; Bart Barlogie; Weijie Chen; Pan Du; Matthias Fischer; Cesare Furlanello; Brandon D Gallas; Xijin Ge; Dalila B Megherbi; W Fraser Symmans; May D Wang; John Zhang; Hans Bitter; Benedikt Brors; Pierre R Bushel; Max Bylesjo; Minjun Chen; Jie Cheng; Jing Cheng; Jeff Chou; Timothy S Davison; Mauro Delorenzi; Youping Deng; Viswanath Devanarayan; David J Dix; Joaquin Dopazo; Kevin C Dorff; Fathi Elloumi; Jianqing Fan; Shicai Fan; Xiaohui Fan; Hong Fang; Nina Gonzaludo; Kenneth R Hess; Huixiao Hong; Jun Huan; Rafael A Irizarry; Richard Judson; Dilafruz Juraeva; Samir Lababidi; Christophe G Lambert; Li Li; Yanen Li; Zhen Li; Simon M Lin; Guozhen Liu; Edward K Lobenhofer; Jun Luo; Wen Luo; Matthew N McCall; Yuri Nikolsky; Gene A Pennello; Roger G Perkins; Reena Philip; Vlad Popovici; Nathan D Price; Feng Qian; Andreas Scherer; Tieliu Shi; Weiwei Shi; Jaeyun Sung; Danielle Thierry-Mieg; Jean Thierry-Mieg; Venkata Thodima; Johan Trygg; Lakshmi Vishnuvajjala; Sue Jane Wang; Jianping Wu; Yichao Wu; Qian Xie; Waleed A Yousef; Liang Zhang; Xuegong Zhang; Sheng Zhong; Yiming Zhou; Sheng Zhu; Dhivya Arasappan; Wenjun Bao; Anne Bergstrom Lucas; Frank Berthold; Richard J Brennan; Andreas Buness; Jennifer G Catalano; Chang Chang; Rong Chen; Yiyu Cheng; Jian Cui; Wendy Czika; Francesca Demichelis; Xutao Deng; Damir Dosymbekov; Roland Eils; Yang Feng; Jennifer Fostel; Stephanie Fulmer-Smentek; James C Fuscoe; Laurent Gatto; Weigong Ge; Darlene R Goldstein; Li Guo; Donald N Halbert; Jing Han; Stephen C Harris; Christos Hatzis; Damir Herman; Jianping Huang; Roderick V Jensen; Rui Jiang; Charles D Johnson; Giuseppe Jurman; Yvonne Kahlert; Sadik A Khuder; Matthias Kohl; Jianying Li; Li Li; Menglong Li; Quan-Zhen Li; Shao Li; Zhiguang Li; Jie Liu; Ying Liu; Zhichao Liu; Lu Meng; Manuel Madera; Francisco Martinez-Murillo; Ignacio Medina; Joseph Meehan; Kelci Miclaus; Richard A Moffitt; David Montaner; Piali Mukherjee; George J Mulligan; Padraic Neville; Tatiana Nikolskaya; Baitang Ning; Grier P Page; Joel Parker; R Mitchell Parry; Xuejun Peng; Ron L Peterson; John H Phan; Brian Quanz; Yi Ren; Samantha Riccadonna; Alan H Roter; Frank W Samuelson; Martin M Schumacher; Joseph D Shambaugh; Qiang Shi; Richard Shippy; Shengzhu Si; Aaron Smalter; Christos Sotiriou; Mat Soukup; Frank Staedtler; Guido Steiner; Todd H Stokes; Qinglan Sun; Pei-Yi Tan; Rong Tang; Zivana Tezak; Brett Thorn; Marina Tsyganova; Yaron Turpaz; Silvia C Vega; Roberto Visintainer; Juergen von Frese; Charles Wang; Eric Wang; Junwei Wang; Wei Wang; Frank Westermann; James C Willey; Matthew Woods; Shujian Wu; Nianqing Xiao; Joshua Xu; Lei Xu; Lun Yang; Xiao Zeng; Jialu Zhang; Li Zhang; Min Zhang; Chen Zhao; Raj K Puri; Uwe Scherf; Weida Tong; Russell D Wolfinger
Journal:  Nat Biotechnol       Date:  2010-07-30       Impact factor: 54.908

4.  Prediction of survival in diffuse large B-cell lymphoma based on the expression of 2 genes reflecting tumor and microenvironment.

Authors:  Ash A Alizadeh; Andrew J Gentles; Alvaro J Alencar; Chih Long Liu; Holbrook E Kohrt; Roch Houot; Matthew J Goldstein; Shuchun Zhao; Yasodha Natkunam; Ranjana H Advani; Randy D Gascoyne; Javier Briones; Robert J Tibshirani; June H Myklebust; Sylvia K Plevritis; Izidore S Lossos; Ronald Levy
Journal:  Blood       Date:  2011-06-13       Impact factor: 22.113

5.  Z-Score: Fenton 2013. Ten-year update.

Authors:  Alvaro Proaño; Romina E Aragón; José Leonidas Proaño
Journal:  J Pediatr (Rio J)       Date:  2014-04-16       Impact factor: 2.197

6.  C-reactive protein and beta-2 microglobulin produce a simple and powerful myeloma staging system.

Authors:  R Bataille; M Boccadoro; B Klein; B Durie; A Pileri
Journal:  Blood       Date:  1992-08-01       Impact factor: 22.113

7.  Consensus recommendations for risk stratification in multiple myeloma: report of the International Myeloma Workshop Consensus Panel 2.

Authors:  Nikhil C Munshi; Kenneth C Anderson; P Leif Bergsagel; John Shaughnessy; Antonio Palumbo; Brian Durie; Rafael Fonseca; A Keith Stewart; Jean-Luc Harousseau; Meletios Dimopoulos; Sundar Jagannath; Roman Hajek; Orhan Sezer; Robert Kyle; Pieter Sonneveld; Michele Cavo; S Vincent Rajkumar; Jesus San Miguel; John Crowley; Hervé Avet-Loiseau
Journal:  Blood       Date:  2011-02-03       Impact factor: 22.113

8.  Multiple myeloma: review of 869 cases.

Authors:  R A Kyle
Journal:  Mayo Clin Proc       Date:  1975-01       Impact factor: 7.616

9.  High serum lactate dehydrogenase level as a marker for drug resistance and short survival in multiple myeloma.

Authors:  M A Dimopoulos; B Barlogie; T L Smith; R Alexanian
Journal:  Ann Intern Med       Date:  1991-12-15       Impact factor: 25.391

10.  Prediction of survival in multiple myeloma based on gene expression profiles reveals cell cycle and chromosomal instability signatures in high-risk patients and hyperdiploid signatures in low-risk patients: a study of the Intergroupe Francophone du Myélome.

Authors:  Olivier Decaux; Laurence Lodé; Florence Magrangeas; Catherine Charbonnel; Wilfried Gouraud; Pascal Jézéquel; Michel Attal; Jean-Luc Harousseau; Philippe Moreau; Régis Bataille; Loïc Campion; Hervé Avet-Loiseau; Stéphane Minvielle
Journal:  J Clin Oncol       Date:  2008-06-30       Impact factor: 44.544

View more
  1 in total

1.  Super-Enhancer Associated Five-Gene Risk Score Model Predicts Overall Survival in Multiple Myeloma Patients.

Authors:  Tingting Qi; Jian Qu; Chao Tu; Qiong Lu; Guohua Li; Jiaojiao Wang; Qiang Qu
Journal:  Front Cell Dev Biol       Date:  2020-12-03
  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.